Danish biotech Genmab (Nasdaq Copenhagen: GEN) has announced top-line results from the Phase III MAIA study of daratumumab in combination with lenalidomide and dexamethasone (DRd) versus the latter two alone, in front-line multiple myeloma.
The study compared these treatments for newly-diagnosed patients who are not candidates for high-dose chemotherapy and autologous stem cell transplant (ASCT).
Daratumumab is marketed under the name Darzalex and is being developed by the Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Biotech.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze